全文获取类型
收费全文 | 675篇 |
免费 | 79篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 66篇 |
妇产科学 | 6篇 |
基础医学 | 96篇 |
口腔科学 | 30篇 |
临床医学 | 72篇 |
内科学 | 137篇 |
皮肤病学 | 19篇 |
神经病学 | 25篇 |
特种医学 | 128篇 |
外科学 | 40篇 |
综合类 | 42篇 |
预防医学 | 24篇 |
眼科学 | 29篇 |
药学 | 12篇 |
肿瘤学 | 33篇 |
出版年
2023年 | 2篇 |
2022年 | 2篇 |
2021年 | 5篇 |
2020年 | 6篇 |
2019年 | 7篇 |
2018年 | 19篇 |
2017年 | 7篇 |
2016年 | 21篇 |
2015年 | 22篇 |
2014年 | 26篇 |
2013年 | 40篇 |
2012年 | 23篇 |
2011年 | 14篇 |
2010年 | 42篇 |
2009年 | 44篇 |
2008年 | 15篇 |
2007年 | 27篇 |
2006年 | 12篇 |
2005年 | 19篇 |
2004年 | 7篇 |
2003年 | 11篇 |
2002年 | 5篇 |
2001年 | 7篇 |
2000年 | 6篇 |
1999年 | 5篇 |
1998年 | 40篇 |
1997年 | 42篇 |
1996年 | 42篇 |
1995年 | 36篇 |
1994年 | 22篇 |
1993年 | 28篇 |
1992年 | 4篇 |
1991年 | 6篇 |
1990年 | 6篇 |
1989年 | 18篇 |
1988年 | 15篇 |
1987年 | 10篇 |
1986年 | 13篇 |
1985年 | 14篇 |
1984年 | 7篇 |
1983年 | 12篇 |
1982年 | 5篇 |
1981年 | 13篇 |
1980年 | 7篇 |
1979年 | 4篇 |
1978年 | 4篇 |
1977年 | 8篇 |
1976年 | 9篇 |
1975年 | 2篇 |
1884年 | 1篇 |
排序方式: 共有762条查询结果,搜索用时 15 毫秒
761.
Marcelo S Nacif Andrew E Arai Joao AC Lima David A Bluemke 《Journal of cardiovascular magnetic resonance》2012,14(1):18
Purpose
Myocardial late gadolinium enhancement was originally validated using higher than label-recommended doses of gadolinium chelate. The objective of this study was to evaluate available evidence for various gadolinium dosing regimens used for CMR. The relationship of gadolinium dose warnings (due to nephrogenic systemic fibrosis) announced in 2008 to gadolinium dosing regimens was also examined.Methods
We conducted a meta-analysis of peer reviewed publications from January, 2004 to December, 2010. Major subject search headings (MeSh) terms from the National Library of Medicine''s PubMed were: contrast media, gadolinium, heart, magnetic resonance imaging; searches were limited to human studies with abstracts published in English. Case reports, review articles, editorials, MRA related papers and all reports that did not indicate gadolinium type or weight-based dose were excluded. For all included references, full text was available to determine the total administered gadolinium dose on a per kg basis. Average and median dose values were weighted by the number of subjects in each study.Results
399 publications were identified in PubMed; 233 studies matched the inclusion criteria, encompassing 19,934 patients with mean age 54.2 ± 11.4 (range 9.3 to 76 years). 34 trials were related to perfusion testing and 199 to myocardial late gadolinium enhancement. In 2004, the weighted-median and weighted-mean contrast dose were 0.15 and 0.16 ± 0.06 mmol/kg, respectively. Median contrast doses for 2005-2010 were: 0.2 mmol/kg for all years, respectively. Mean contrast doses for the years 2005-2010 were: 0.19 ± 0.03, 0.18 ± 0.04, 0.18 ± 0.10, 0.18 ± 0.03, 0.18 ± 0.04 and 0.18 ± 0.04 mmol/kg, respectively (p for trend, NS). Gadopentetate dimeglumine was the most frequent gadolinium type [114 (48.9%) studies]. No change in mean gadolinium dose was present before, versus after the Food and Drug Administration (FDA) black box warning (p > 0.05). Three multi-center dose ranging trials have been published for cardiac MRI applications.Conclusion
CMR studies in the peer-reviewed published literature routinely use higher gadolinium doses than regulatory agencies indicated in the package leaflet. Clinical trials should be supported to determine the appropriate doses of gadolinium for CMR studies. 相似文献762.